State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 7,809,060 shares of Intellia Therapeutics Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported 7,809,060 shares of Intellia Therapeutics Inc common stock, representing 5.6% of the class.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote of 7,473,384 shares, with sole voting power of 0 shares.
  • Shared dispositive power: The filing reported shared power to dispose of 7,809,060 shares, with sole dispositive power of 0 shares.
  • Event date: The date of the event requiring the filing was September 30, 2026.
  • Filing subsidiaries: Five subsidiaries are identified as the entities that acquired the securities, all classified as investment advisers (IA): SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd.
  • Signing officer: The statement was signed by Alok Maheshwary, Senior Vice President, dated November 9, 2026.

State Street's Schedule 13G Disclosure for Intellia Therapeutics

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its position in Intellia Therapeutics Inc (CUSIP 45826J105), a Cambridge, Massachusetts-based issuer whose principal offices are located at 40 Erie Street, Suite 130. The filing covers common stock holdings as of a triggering event dated September 30, 2026, and was submitted on November 10, 2026.

According to the filing, State Street reported aggregate beneficial ownership of 7,809,060 shares, equating to 5.6% of the outstanding class. The company disclosed 0 shares held with sole voting power and 7,473,384 shares held with shared voting power. For dispositive authority, the filing reported 0 shares with sole power and 7,809,060 shares with shared power to dispose or direct disposition. State Street is classified in the filing as a parent holding company (type "HC").

The filing identifies five subsidiaries through which the securities were acquired, each classified as an investment adviser: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing certifies, in the words of Item 10, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 5.6% beneficial ownership stake of 7,809,060 shares in Intellia Therapeutics Inc common stock via a Schedule 13G, with the triggering event dated September 30, 2026, and the statement signed November 9, 2026.